adakveo
novartis europharm limited - crizanlizumab - anemija, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
leqvio
novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - sredstva za modifikaciju lipida - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karcinom, ne-malih stanica pluća - antineoplastična sredstva - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
locametz
novartis europharm limited - gozetotide - radionuklidno slikanje - dijagnostički radiofarmaceutici - ovaj je lijek samo za dijagnostičku uporabu. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - tumori prostate, Кастраци-uporan - terapeutski radiofarmaceutski pripravci - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
ronix 4 mg/5 ml koncentrat za rastvor za infuziju
corapharm d.o.o. - zoledronska kiselina - koncentrat za rastvor za infuziju - 4 mg/5 ml - 5 ml koncentrata za rastvor za infuziju sadrži: 4 mg zoledronske kiseline
gemcitabine venus 200 mg/1 bočica prašak za rastvor za infuziju
corapharm d.o.o. - gemcitabin - prašak za rastvor za infuziju - 200 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži 200 mg gemcitabina (u obliku gemcitabinhidrohlorida)
gemcitabine venus 1000 mg/1 bočica prašak za rastvor za infuziju
corapharm d.o.o. - gemcitabin - prašak za rastvor za infuziju - 1000 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži 1000 mg gemcitabina (u obliku gemcitabinhidrohlorida)
tigecid 50 mg/1 bočica prašak za rastvor za infuziju
corapharm d.o.o. - tigeciklin - prašak za rastvor za infuziju - 50 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži: 50 mg tigeciklina
meropenem venus 500 mg/1 bočica prašak za rastvor za injekciju/infuziju
corapharm d.o.o. - Меропенем - prašak za rastvor za injekciju/infuziju - 500 mg/1 bočica - jedna bočica sa praškom za rastvor za injekciju/infuziju sadrži 500 mg meropenema, u obliku meropenemtrihidrata